
Biotron Limited (BIT) is a clinical stage Australian Biotechnology Company based in Sydney, Australia. The company is involved in the development and commercialization of a novel small molecule approach that has the potential to treat several serious viral diseases. The technology targets viroporin proteins which enables the pathogenicity of several viruses including hepatitis C, HIV-1, Dengue, Zika, Influenza and Respiratory Syncytial Virus (RSV). The company has operations in Australia.